References
- 1. HAMM C, BASSAND J, AGEWALL S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32:2999-3054.
- 2. KING S, SMITH S, HIRSHFELD J, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:172-209.
- 3. EIKELBOOM J, HIRSH J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost 2007; 5(suppl 1):255-63.
- 4. COLLINS R, MACMAHON S, FLATHER M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313:652-9.
- 5. FRAGMIN DURING INSTABILITY IN CORONARY ARTERY DISEASE (FRISC) STUDY GROUP. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347:561-8.
- 6. YUSUF S, MEHTA S, XIE C, et al. Effects of reviparin, a low-molecular weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293:427-35.
- 7. POLDERMANS D, BAX J, BOERSMA E, et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery. Eur Heart J 2009; 30:2769-812.
- 8. BROTT T, HALPERIN J, ABBARA S, et al. 2011 ASA/ACCF/AHA Guideline on the management of the patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol 2011; 57:e16-94.
- 9. WIJNS W, KOLH P, DANCHIN N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501-55.